

CURRICULUM VITAE

PARASKEVI V. VOULGARI, MD

Professor of Rheumatology

Department of Internal Medicine, Medical School

University of Ioannina, Greece

Ioannina, 2019

Name: Paraskevi V. Voulgari
 Citizenship: Greek
 Languages: English, French
 Address (Office): Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, GREECE
 MD License number: 8910/1990
 Tel: #30 26510 7503/99755
 Fax: #30 2650 07054
 e-mail: pvoulgar@uoi.gr

EDUCATION

1990: MD, Cum laude, Medical School, University of Ioannina, Ioannina-GREECE
 1998: Doctoral Thesis, Cum laude, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina-GREECE
 1998: Acquisition of specialty of Rheumatology after oral exams
 2011-2013: A six- month training course in musculoskeletal ultrasonography in Section of Musculoskeletal Ultrasonography, Department of Rheumatology, Universita Politecnica delle Marche, Italy (Director: Professor Walter Grassi)

PROFESSIONAL – CLINICAL EXPERIENCE

Sept 1990 – Dec 1991 Physician in a rural area (Louros, Preveza)
 Dec 1991 – April 1993 Resident in Medicine, Department of Internal Medicine, General Hospital, Arta Greece.
 April 1993 – April 1994 Resident in Medicine, Department of Internal Medicine, Hatzikosta General Hospital, Ioannina Greece.
 April 1994 – April 1998 Resident in Rheumatology, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina Greece.
 June 1998 – Sept 2002 Fellow in Rheumatology Department of Internal Medicine, Medical School, University of Ioannina, Ioannina Greece.
 Sept 2002 – April 2007 Lecturer of Rheumatology, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
 April 2007 – Sept 2012 Assistant Professor of Rheumatology, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
 Sept 2012 – Jan 2017 Associate Professor of Rheumatology, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
 Jan 2017 – present Professor of Rheumatology, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

TEACHING EXPERIENCE

2002 – Present Teaching of 3rd, 4th, 5th and 6th year medical students in the Medical School of the University of Ioannina (5 different courses).
 2002 – Present Teaching in educational programmes in the Department of Internal Medicine, Medical School, University of Ioannina.
 2005 – 2015 Teaching in postgraduate courses in Ioannina (3 courses) and Athens (1 course).
 2015 – Present Responsible for the elective course Molecular Immunology.

PROFESSIONAL MEMBERSHIPS

- Ioannina Medical Association
- Member of Greek Society of Rheumatology
- The New York Academy of Sciences (till 2013)

RESEARCH

My research interests include epidemiological studies, clinical studies concerning autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, scleroderma, etc). In addition, I have participated in several projects in the Department of Internal Medicine.

GUEST PEER REVIEWER

- Annals of Medicine
- Clinical Investigation
- European Journal of Internal Medicine
- European Journal of Clinical Investigation
- Expert Review of Clinical Immunology
- Future Rheumatology
- International Journal of Clinical Rheumatology
- Scandinavian Journal of Rheumatology
- Therapy
- Hippokratia Medicine Journal

EDITORIAL ACTIVITIES

- 2010 – 2013 Associate Editor of BMC Musculoskeletal Disorders.
- 2010 – 2014 Member of the Editorial Board of ISRN Rheumatology.
- 2015 – Present Member of the Editorial Board of Mediterranean Journal of Rheumatology.

POSTGRADUATED RESEARCH WORK, PhD THESIS ADVISOR AND COMMITTEE MEMBER

- 2005 – Present Participate in 28 PhD thesis committees (9 completed).
- 2007 – 2013 Advisor of 7 completed postgraduated research works.
- 2008 – Present Advisor in 5 PhD thesis (in progress).

MEETING ACTIVITIES

- 1993 – 2015 242 announcements in Greek and International meetings.
- 1996 – Present 150 published abstracts.
- 2002 – Present Invited speaker in 43 Greek Symposia and courses and participation in 40 round tables.
- 2003 – 2005 Editing in 3 Greek Conference Proceedings.
- 2005 – 2014 Member of 11 organizing symposium committees.

BOOKS

- 2003 Notes of Immunology for medical students Medical School, University of Ioannina.
- 2019 Pelechas, E., Kaltsonoudis, E., Voulgari, P., Drosos, A. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Springer 12 Jan.

CHAPTERS IN BOOKS

- 1986 – 2006 Chapters in 4 Greek books

HONORS – AWARDS

- 1996 International Congress on Immunointervention: The role of Neoral in immune-based disease, Rome, Italy.
- 1998 – 2012 18 founded projects by Hellenic Rheumatology Society and 2 founded by governmental and European sources.
- 2004 – 2014 10 Greek awards for research work

PUBLICATIONS

1. Akritidis NK, Giannakakis IA, Mastora MM, Giouglis TP, Voulgari PV, Rafu TA: Can Acyclovir Cure Chronic Idiopathic Thrombocytopenic Purpura? A case study. *Herpes* 319: 99-100, 1994 (**Impact Factor: 0 – Citations: 0**)
2. Voulgari PV, Zikou AK, Bai M, Drosos AA: Subcutaneous lesion as the initial manifestation of sarcoidosis. *Eur J Intern Med* 8: 119-120, 1997 (**Impact Factor: 2,891 – Citations: 0**)
3. Drosos AA, Georgiou P, Politi EN, Voulgari PV: D-penicillamine in early rheumatoid arthritis. *Clin Exp Rheumatol* (letter) 15: 580-581, 1997 (**Impact Factor: 2,724 – Citations: 6**)
4. Drosos AA, Alamanos I, Voulgari PV, Psychos DN, Katsaraki A, Papadopoulos I, Dimou G, Siozos Ch: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. *J Rheumatol* 24: 2129-2133, 1997 (**Impact Factor: 3,187 – Citations: 108**)
5. Damigos D, Siafaka V, Voulgari PV, Liakos A, Drosos AA: Critical notes on the article: The impact of life events on patients with rheumatoid arthritis: a psychological myth? (letter) *Clin Exp Rheumatol* 16: 350, 1998 (**Impact Factor: 2,724 – Citations: 0**)
6. Drosos AA, Voulgari PV, Papadopoulos IA, Politi EN, Georgiou PE, Zikou AK: Cyclosporine-A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. *Clin Exp Rheumatol*, 16: 695-701, 1998 (**Impact Factor: 2,724 – Citations: 28**)
7. Voulgari PV, Drosos AA: Esonarimod. *Curr Opin Antiinflam Immunomod* 1: 162-167, 1999 (**Impact Factor: 0 – Citations: 0**)
8. Drosos AA, Voulgari PV, Psychos DN, Tsifetaki N, Bai M: Sicca syndrome in patients with sarcoidosis. *Rheumatol Int* 18: 177-180, 1999 (**Impact Factor: 1,516 – Citations: 42**)
9. Voulgari PV, Efremidis SC, Drosos AA: Rheumatoid resorptive arthropathy. *Clin Exp Rheumatol* 17: 474-476, 1999 (**Impact Factor: 2,724 – Citations: 3**)
10. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. *Clin Immunol* 92:153-160, 1999 (**Impact Factor: 3,672 – Citations: 95**)
11. Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA, Tsianos EV: Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. *Eur J Gastroenterol Hepatol* 12: 67-74, 2000 (**Impact Factor: 2,253 – Citations: 61**)
12. Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou Ch, Drosos AA: Prevalence of Raynaud's phenomenon in a healthy Greek population. *Ann Rheum Dis* 59: 206-210, 2000 (**Impact Factor: 10,377– Citations: 36**)
13. Drosos AA, Voulgari PV, Katsaraki A, Zikou AK: Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. *Rheumatol Int* 19: 113-118, 2000 (**Impact Factor: 1,516 – Citations: 34**)
14. Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM: Erythema nodosum: the underlying conditions. *Clin Rheumatol* 19: 212-216, 2000 (**Impact Factor: 1,696 – Citations: 71**)
15. Voulgari PV, Hatzimichael EC, Tsiara S, Tzallas C, Drosos AA, Bourantas KL: Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. *Eur J Haematol* 66: 31-36, 2001 (**Impact Factor: 2,066 – Citations: 11**)
16. Drosos AA, Voulgari PV: Long-term efficacy and toxicity of a combination therapy in rheumatoid arthritis patients. *Clin Exp Rheumatol* (letter) 19: 111, 2001 (**Impact Factor: 2,724 – Citations: 1**)
17. Kastanioudakis I, Ziavra N, Voulgari PV, Exarchakos G, Skevas A, Drosos AA: Ear involvement in systemic lupus erythematosus patients. A comparative study. *J Laryngol Otol* 116: 103-107, 2002 (**Impact Factor: 0,672 – Citations: 47**)
18. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA: Disease modifying anti-rheumatic drugs in early rheumatoid arthritis: a long-term observational study. *J Rheumatol* 29: 261-266, 2002 (**Impact Factor: 3,187 – Citations: 48**)
19. Voulgari PV, Vartholomatos G, Kaiafas P, Bourantas KL, Drosos AA: Rheumatoid arthritis and B-cell chronic lymphocytic leukemia. *Clin Exp Rheumatol* 20: 63-65, 2002 (**Impact Factor: 2,724 – Citations: 10**)

20. Ioannidis JPA, Tarassi K, Papadopoulos IA, Voulgari PV, Boki KA, Papasteriades ChA, Drosos AA: Shared epitopes and rheumatoid arthritis: disease associations in Greece and meta-analysis of Mediterranean European populations. *Semin Arthritis Rheum* 31: 361-370, 2002 (**Impact Factor: 3,925 – Citations: 31**)
21. Temekonidis TI, Georgiadis AN, Alamanos Y, Bougias DV, Voulgari PV, Drosos AA: Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. *Ann Rheum Dis* 61: 822-825, 2002 (**Impact Factor: 10,377– Citations: 52**)
22. Voulgari PV, Drosos AA: Gingival hyperplasia associated with cyclosporin A. *J Rheumatol* 29: 2466, 2002 (**Impact Factor: 3,187 – Citations: 3**)
23. Tsanadis GD, Chouliara ST, Voulgari PV, Makrydimas GV, Drosos AA: Outcome of pregnancy in a patient with relapsing polychondritis and pyoderma gangrenosum (letter) *Clin Rheumatol* 21: 538, 2002 (**Impact Factor: 1,696 – Citations: 10**)
24. Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA: Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. *Lupus* 11: 722-729, 2002 (**Impact Factor: 2,197 – Citations: 61**)
25. Papadopoulos IA, Katsimbri P, Alamanos Y, Voulgari PV, Drosos AA: Early rheumatoid arthritis patients: relationship of age. *Rheumatol Int* 23: 70-74, 2003 (**Impact Factor: 1,516 – Citations: 38**)
26. Alamanos Y, Voulgari PV, Siozos C, Katsimbri P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA: Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. *Rheumatol Int* 30 : 731-735, 2003 (**Impact Factor: 1,516 – Citations: 46**)
27. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, Picco P, Taglietti M, Zulian F, Ten Cate R, Sztajn bok FR, Voulgari PV, Drosos AA: Primary Sjogren’s syndrome in the paediatric age: a multicentre survey. *Eur J Pediatr* 162: 661-665, 2003 (**Impact Factor: 1,890 – Citations: 71**)
28. Alamanos Y, Voulgari PV, Parassava M, Tsamandouraki K, Drosos AA: Survival and mortality rates of systemic lupus erythematosus in northwest Greece. Study of a 21–years incidence cohort (Letter). *Rheumatology* 42: 1122-1123, 2003 (**Impact Factor: 4,475 – Citations: 28**)
29. Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, Eftaxias V, Voulgari PV, Psilas K, Drosos AA: Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren’s syndrome: a randomized 12 week controlled study. *Ann Rheum Dis* 62: 1204-1207, 2003 (**Impact Factor: 10,377– Citations: 80**)
30. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA: Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. *Ann Rheum Dis* 62:1218-1220, 2003 (**Impact Factor: 10,377– Citations: 66**)
31. Voulgarelis M, Voulgari PV, Serelis J, Drosos AA, Skopouli FN: Visceral leishmaniasis resembling systemic lupus erythematosus. *Clin Rheumatol* 22: 452-455, 2003 (**Impact Factor: 1,696 – Citations: 11**)
32. Alamanos Y, Papadopoulos NG, Voulgari PV, Siozos C, Psychos DN, Tympanidou M, Drosos AA: Epidemiology of psoriatic arthritis in northwest Greece, 1982-2002. *J Rheumatol* 30: 2641-2644, 2003 (**Impact Factor: 3,187 – Citations: 51**)
33. Voulgari PV, Chaidos A, Tzouvara E, Alymara V, Alamanos Y, Drosos AA, Bourantas KL: Antierythropoietin antibodies in thalassemia patients. *Ann Hematol* 83: 22-27, 2004 (**Impact Factor: 2,634 – Citations: 7**)
34. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA: Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. *Rheumatology* 43: 615-618, 2004 (**Impact Factor: 4,475 – Citations: 74**)
35. Voulgari PV, Papadopoulos IA, Alamanos Y, Katsaraki A, Drosos AA: Early rheumatoid arthritis: Does gender influence disease expression? *Clin Exp Rheumatol* 22: 165-170, 2004 (**Impact Factor: 2,724 – Citations: 10**)
36. Drosos AA, Georgiadis AN, Metafratzi ZM, Voulgari PV, Efremidis SC, Bai M: Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) in a patient with primary Sjogren’s syndrome (case report). *Scand J Rheumatol* 33: 119-122, 2004 (**Impact Factor: 3,187 – Citations: 8**)
37. Alamanos Y, Voulgari PV, Drosos AA: Epidemiology of rheumatic diseases in Greece. *J Rheumatol* 31: 1669-1670, 2004 (**Impact Factor: 3,187 – Citations: 4**)

38. Voulgari PV, Pappas GA, Liberopoulos EN, Elisaf M, Skopouli FN, Drosos AA: Visceral leishmaniasis resembling systemic lupus erythematosus (Letter). *Ann Rheum Dis* 63: 1348-1349, 2004 (**Impact Factor: 10,377– Citations: 17**)
39. Alamanos Y, Voulgari PV, Drosos AA: Rheumatoid arthritis in southern Europe: epidemiological, clinical, radiological, and genetic considerations. *Curr Rheum Rev* 1: 33-36, 2005 (**Impact Factor: 0 – Citations: 11**)
40. Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA: Infliximab treatment in ankylosing spondylitis: an observational study. *Ann Rheum Dis* 64: 940-942, 2005 (**Impact Factor: 10,377– Citations: 35**)
41. Voulgari PV, Papazisi D, Bai M, Zagorianakou P, Assimakopoulos D, Drosos AA: Laryngeal involvement in rheumatoid arthritis. *Rheumatol Int* 25: 321-325, 2005 (**Impact Factor: 1,516 – Citations: 40**)
42. Kozanidou VI, Theocharis AD, Georgiadis A, Voulgari PV, Drosos AA, Karamanos NK: Signal transduction by IL-2 and its receptors as target in treatment of rheumatoid arthritis. *Curr Drug Targets Immune Endocr Metabol Disord* 5: 41-50, 2005 (**Impact Factor: 3,021 – Citations: 12**)
43. Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, Drosos AA: Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. *Semin Arthritis Rheum* 34: 714-720, 2005 (**Impact Factor: 3,925 – Citations: 49**)
44. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA: Infliximab therapy in established rheumatoid arthritis: an observational study. *Am J Med* 118: 515-520, 2005 (**Impact Factor: 5,003 – Citations: 70**)
45. Zikou AK, Alamanos Y, Argyropoulou MI, Tsifetaki N, Tsampoulas C, Voulgari PV, Efremidis SC, Drosos AA: Radiological cervical spine involvement in patients with rheumatoid arthritis: a cross sectional study. *J Rheumatol* 32: 801-806, 2005 (**Impact Factor: 3,187 – Citations: 35**)
46. Voulgari PV, Karali A, Alymara V, Chaidos A, Bourantas KL, Drosos AA: Systemic lupus erythematosus in a patient with beta-thalassemia major (Letter). *Clin Exp Rheumatol* 23: 278, 2005 (**Impact Factor: 2,724 – Citations: 1**)
47. Voulgari PV, Tsifetaki N, Metafratzi ZM, Zioga A, Acritidis NC, Drosos AA: A single pulmonary rheumatoid nodule masquerading as malignancy. *Clin Rheumatol* 24: 556-559, 2005 (**Impact Factor: 1,696 – Citations: 6**)
48. Zikou AK, Argyroupoulou MI, Alamanos Y, Tsifetaki N, Tsampoulas C, Voulgari PV, Efremidis SC, Drosos AA: Magnetic resonance imaging findings of the cervical spine in patients with rheumatoid arthritis. A cross-sectional study. *Clin Exp Rheumatol* 23: 665-70, 2005 (**Impact Factor: 2,724 – Citations: 13**)
49. Nikas SN, Voulgari PV, Takalou IP, Katsimbri P, Drosos AA: Healing of psoriatic skin lesions and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. *Ann Rheum Dis* 64: 1665-1667, 2005 (**Impact Factor: 10,377– Citations: 5**)
50. Argyropoulou MI, Glatzouni A, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, Drosos AA: Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with infliximab. *Joint Bone Spine* 72: 557-561, 2005 (**Impact Factor: 2,901 – Citations: 28**)
51. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA: Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? *Clin Exp Rheumatol* 23: 861-866, 2005 (**Impact Factor: 2,724 – Citations: 97**)
52. Voulgari PV, Zikou AK, Drosos AA: Subcutaneous lesions in dermatomyositis (clinical vignette). *Rheumatology* 45: 165, 2006 (**Impact Factor: 4,475 – Citations: 1**)
53. Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA: The efficacy and safety of switching from infliximab to adalimumab. A comparative controlled study. *Ann Rheum Dis* 65: 257-260, 2006 (**Impact Factor: 10,377– Citations: 93**)
54. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA: Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. *Rheumatology* 45: 187-191, 2006 (**Impact Factor: 4,475 – Citations: 104**)
55. Hyphantis TN, Bai M, Siafaka V, Georgiadis AN, Voulgari PV, Mavreas V, Drosos AA: Psychological distress and personality traits in early rheumatoid arthritis: a preliminary survey. *Rheumatol Int* 26: 828-836, 2006 (**Impact Factor: 1,516 – Citations: 24**)

56. Dalavanga VA, Voulgari PV, Georgiadis AN, Leontaridi C, Katsenos S, Vassiliou M, Drosos AA, Constantopoulos SH: Lymphocytic alveolitis: *Rheumatol Int* 26: 799-804, 2006 (**Impact Factor: 1,516 – Citations: 10**)
57. Voulgari PV, Alamanos Y, Drosos AA: Persistent clinical response of infliximab therapy in patients with refractory rheumatoid arthritis, over a 3-year period. *Curr Clin Pharmacol* 1: 103-108, 2006 (**Impact Factor: 0 – Citations: 3**)
58. Zikou AK, Argyropoulou MI, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, Drosos AA: Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. *J Rheumatol* 33: 219-223, 2006 (**Impact Factor: 3,187 – Citations: 37**)
59. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA: Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. *Semin Arthritis Rheum* 26: 173-181, 2006 (**Impact Factor: 3,925 – Citations: 44**)
60. Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. *Semin Arthritis Rheum* 36: 182-188, 2006 (**Impact Factor: 3,925 – Citations: 308**)
61. Voulgari PV, Drosos AA: Adalimumab for rheumatoid arthritis. *Expert Opin Biol Ther* 6: 1349-1360, 2006 (**Impact Factor: 3,743 – Citations: 15**)
62. Nikas SN, Voulgari PV, Drosos AA: Urticaria and angioedema-like skin reactions in a patient treated with adalimumab. *Clin Rheumatol* 26: 787-788, 2007 (**Impact Factor: 1,696 – Citations: 38**)
63. Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A: Multiple sclerosis associated with systemic sclerosis. *Rheumatol Int* 27: 771-773, 2007 (**Impact Factor: 1,516 – Citations: 11**)
64. Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos AA: Infliximab in refractory psoriatic arthritis with severe psoriasis. A two-year experience. *Ann Rheum Dis* 66: 270-271, 2007 (**Impact Factor: 10,377– Citations: 6**)
65. Hyphantis TN, Tsifetaki N, Pappa C, Voulgari PV, Siafaka V, Bai M, Alamanos Y, Drosos AA, Mavreas V: Clinical Features and personality traits associated with psychological distress in systemic sclerosis patients. *J Psychosom Res* 62: 47-56, 2007 (**Impact Factor: 2,842 – Citations: 35**)
66. Venetsanopoulou AI, Voulgari PV, Alamanos Y, Papadopoulos CG, Markatseli TE, Drosos AA: Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. *Rheumatol Int* 27: 935-939, 2007 (**Impact factor: 1,516 – Citations: 16**)
67. Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA: Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. *Rheumatol Int* 27: 1057-1061, 2007 (**Impact factor: 1,516 – Citations: 26**)
68. Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsanopoulou AI, Drosos AA: Combined tumour necrosis factor- α and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF- α therapy and explain controversies of studies based on a single polymorphism. *Rheumatology (Oxford)* 46: 1034-1035, 2007 (**Impact factor: 4,475 – Citations: 43**)
69. Hyphantis TN, Tsifetaki N, Siafaka V, Voulgari PV, Pappa C, Bai M, Palieraki K, Venetsanopoulou A, Mavreas V, Drosos AA: The Impact of Psychological Functioning upon Systemic Sclerosis Patients' Quality of Life. *Semin Arthritis Rheum* 37: 81-92, 2007 (**Impact factor: 3,925 – Citations: 35**)
70. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA: Granuloma annulare induced by anti-tumor necrosis factor therapy. *Ann Rheum Dis* 67: 567-570, 2008 (**Impact factor: 10,377– Citations: 55**)
71. Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA: Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. *Semin Arthritis Rheum* 37: 293-298, 2008 (**Impact factor: 3,925 – Citations: 16**)
72. Voulgari PV: Emerging drugs for rheumatoid arthritis. *Expert Opin Emerg Drugs* 13: 175-196, 2008 (**Impact factor: 3,058 – Citations: 17**)

73. Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, Drosos AA: Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. *Semin Arthritis Rheum* 38: 13-19, 2008 (**Impact factor: 3,925 – Citations: 79**)
74. Papagoras CE, Botzoris VG, Voulgari PV, Drosos AA: A mandibular osteolytic lesion in a systemic lupus erythematosus patient on long-standing bisphosphonate therapy. *Rheumatol Int* 28: 1287–1289, 2008 (**Impact factor: 1,516 – Citations: 0**)
75. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. *J Rheumatol* 35: 1354-1358, 2008 (**Impact factor: 3,187 – Citations: 93**)
76. Voulgari PV, Drosos AA: Catastrophic Rheumatoid Arthritis. *J Rheumatol* 35: 2062-2063, 2008 (**Impact factor: 3,187 – Citations: 5**)
77. Papadopoulos CG, Voulgari PV, Zioga A, Miltiadous GA, Nicolopoulos P, Elisaf MS, Drosos AA: Significant improvement of axillary artery stenosis in a 67 year-old woman with giant cell arteritis. *Clin Exp Rheumatol* 26(3 Suppl 49): S151-152, 2008 (**Impact Factor: 2,724 – Citations: 1**)
78. Chatzikiyakidou A, Georgiou I, Voulgari PV, Georgiadis AN, Argyriou ES, Drosos AA: Glucocorticoid receptor variants may predispose to rheumatoid arthritis susceptibility. *Scand J Rheumatol* 30: 1-5, 2009 (**Impact factor: 2,527 – Citations: 4**)
79. Stergiouli I, Tsifetaki N, Voulgari PV, Kosta P, Argyropoulou MI, Drosos AA: Ankylosing spondylitis and IgA deficiency. *Joint Bone Spine* 76: 110-111, 2009 (**Impact factor: 2,901 – Citations: 1**)
80. Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA: Fertility and Reproduction in Male Patients with Ankylosing Spondylitis Treated with Infliximab. *J Rheumatol* 36: 351-354, 2009 (**Impact factor: 3,187 – Citations: 36**)
81. Papagoras CE, Argyropoulou MI, Voulgari PV, Vrabie I, Zikou AK, Drosos AA: A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. *Clin Exp Rheumatol* 27(1): 124-127, 2009 (**Impact factor: 2,724 – Citations: 9**)
82. Botzoris VG, Argyropoulou MI, Voulgari PV, Zikou AK, Drosos AA: Heterotopic ossification in systemic sclerosis. *Scand J Rheumatol* 38: 317-319, 2009 (**Impact factor: 2,527 – Citations: 4**)
83. Papagoras C, Voulgari PV, Drosos AA: Long-term use of adalimumab in the treatment of rheumatic diseases. *Open Access Rheumatol Res Rev* 1: 51-68, 2009 (**Impact factor: 0 - Citations: 2**)
84. Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M, Polyzoidis K, Kyritsis A, Alamanos Y: Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005-2007. *Neuroepidemiology* 30: 89-95, 2009 **Impact factor: 2,558 – Citations: 12**)
85. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN: Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. *Fund Clin Pharmacol* 23: 595-600, 2009 (**Impact factor: 2,121 – Citations: 33**)
86. Exarchou S, Voulgari P, Markatseli T, Zioga A, Drosos A: Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. *Scand J Rheumatol* 38: 328-331, 2009 (**Impact factor: 2,527 – Citations: 55**)
87. Hyphantis T, Tomenson B, Paika V, Almyroudi A, Pappa C, Tsifetaki N, Voulgari PV, Drosos AA, Pavlidis N, Creed F: Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders. *Qual Life Res* 18: 1029-1042, 2009 (**Impact Factor: 2,486 - Citations: 18**)
88. Chatzikiyakidou A, Georgiou I, Voulgari PV, Drosos AA: The role of tumor necrosis factor (TNF)- α and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. *Clin Exp Rheumatol* 27: 645-648, 2009 (**Impact factor: 2,724 – Citations: 18**)
89. Bai M, Tomenson B, Creed F, Mantis D, Tsifetaki N, Voulgari PV, Drosos AA, Hyphantis TN: The role of psychological distress and personality variables in the disablement process in rheumatoid arthritis. *Scand J Rheumatol* 38: 419-430, 2009 (**Impact factor: 2,527 – Citations: 32**)
90. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA: Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. *Clin Exp Rheumatol* 27: 996-998, 2009 (**Impact factor: 2,724 – Citations: 19**)

91. Voulgari PV, Paschou S, Svarna E, Tsifetaki N, Drosos AA: Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment. *J Rheumatol* 37: 190-191, 2010 (**Impact factor: 3,187 – Citations: 7**)
92. Papagoras C, Kitsos G, Voulgari PV, Zikou AK, Argyropoulou MI, Zioga A, Drosos AA: Periocular xanthogranuloma: A forgotten entity? *Clin Ophthalmol* 4: 105-110, 2010 (**Impact factor: 0 – Citations: 6**)
93. Papagoras C, Voulgari PV, Drosos AA: Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. *Autoimmun Rev* 9: 574-582, 2010 (**Impact factor: 7,933 – Citations: 35**)
94. Saougou I, Markatseli TE, Voulgari PV, Drosos AA: Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study. *Joint Bone Spine* 77: 325-329, 2010 (**Impact factor: 2,901 – Citations: 14**)
95. Saougou I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA: A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. *Clin Rheumatol* 29: 1455-1459, 2010 (**Impact Factor: 1,696 – Citations: 10**)
96. Chatzikiyakidou A, Voulgari PV, Georgiou I, Drosos AA: The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. *Scand J Immunol* 71: 382-385, 2010 (**Impact factor: 1,739 – Citations: 58**)
97. Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP: Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. *J Neuroimmunol* 226: 136-142, 2010 (**Impact factor: 2,467 – Citations: 19**)
98. Goulia P, Voulgari PV, Tsifetaki N, Drosos AA, Hyphantis T: Comparison of health-related quality of life and associated psychological factors between younger and older patients with established rheumatic disorders. *Aging Ment Health* 14: 819-827, 2010 (**Impact factor: 1,781 – Citations: 17**)
99. Voulgari PV: Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. *Expert Rev Clin Immunol* 6: 721-733, 2010 (**Impact factor: 2,484 – Citations: 12**)
100. Chatzikiyakidou A, Voulgari PV, Georgiou I, Drosos AA: A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. *Joint Bone Spine* 77: 411-413, 2010 (**Impact factor: 2,901 – Citations: 58**)
101. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN: Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. *Clin Exp Rheumatol* 28: 880-883, 2010 (**Impact factor: 2,724 – Citations: 18**)
102. Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA: Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study. *Semin Arthritis Rheum* 40: 398-406, 2011 (**Impact Factor: 3,925 – Citations: 20**)
103. Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA: Prognostic Factors of Radiological Damage in Rheumatoid Arthritis: A 10-year Retrospective Study. *J Rheumatol* 38: 44-52, 2011 (**Impact factor: 3,187 – Citations: 28**)
104. Evnouchidou I, Kamal RP, Seregin SS, Goto Y, Tsujimoto M, Hattori A, Voulgari PV, Drosos AA, Amalfitano A, York IA, Stratikos E: Cutting Edge: Coding Single Nucleotide Polymorphisms of Endoplasmic Reticulum Aminopeptidase 1 Can Affect Antigenic Peptide Generation In Vitro by Influencing Basic Enzymatic Properties of the Enzyme. *J Immunol* 186: 1909-1913, 2011 (**Impact factor: 4,922 – Citations: 54**)
105. Chatzikiyakidou A, Voulgari PV, Drosos AA: What is the role of HLA-B27 in spondyloarthropathies? *Autoimmun Rev* 10: 464-468, 2011 (**Impact factor: 7,933 – Citations: 24**)
106. Hyphantis T, Palieraki K, Voulgari PV, Tsifetaki N, Drosos AA: Coping with health-stressors and defense styles associated with health-related quality of life in patients with systemic lupus erythematosus. *Lupus* 20: 893-903, 2011 (**Impact factor: 2,197 – Citations: 25**)
107. Hyphantis T, Kotsis K, Voulgari PV, Tsifetaki N, Creed F, Drosos AA: Diagnostic accuracy, internal consistency and convergent validity of the Greek version of PHQ-9 in diagnosing depression in

- rheumatological disorders. *Arthritis Care Res (Hoboken)* 63: 1313-1321, 2011 (**Impact factor: 4,713 – Citations: 22**)
108. Hyphantis T, Mantis D, Voulgari PV, Tsifetaki N, Drosos AA: The psychological defensive profile of primary Sjögren's syndrome patients and its relationship to health-related quality of life. *Clin Exp Rheumatol* 29: 485-493, 2011 (**Impact factor: 2,724 – Citations: 5**)
 109. Derdemezis CS, Voulgari PV, Drosos AA, Kiortsis DN: Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship? *Clin Exp Rheumatol* 29: 712-727, 2011 (**Impact factor: 2,724 – Citations: 28**)
 110. Kosta PE, Voulgari PV, Zikou AK, Drosos AA, Argyropoulou MI: The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis. *Arthritis Res Ther* 13: R84, 2011 (**Impact factor: 3,753 – Citations: 12**)
 111. Voulgari PV: Rheumatological manifestations in inflammatory bowel disease. *Ann Gastroenterol* 24: 173-180, 2011 (**Impact factor: 0 – Citations: 6**)
 112. Chatzikiyriakidou A, Voulgari PV, Georgiou I, Drosos AA: Identification of the semaphorin receptor Plexin-A2 as a candidate gene for susceptibility to ankylosing spondylitis. *Clin Exp Rheumatol* 29: 894, 2011 (**Impact factor: 2,724 – Citations: 0**)
 113. Pliakou XI, Koutsouka FP, Damigos D, Bourantas KL, Briasoulis EC, Voulgari PV: Rheumatoid arthritis in patients with hemoglobinopathies. *Rheumatol Int* 32: 2889-2892, 2012 (**Impact factor: 1,516 – Citations: 4**)
 114. Iliou C, Anthis N, Tsifetaki N, Kitsos G, Voulgari PV: Corneal melt in a woman with longstanding rheumatoid arthritis. *Arthritis Rheum* 64: 253, 2012 (**Impact factor: 7,764 – Citations: 5**)
 115. Chatzikiyriakidou A, Voulgari PV, Georgiou I, Drosos AA: miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. *Autoimmun Rev* 11: 636-641, 2012 (**Impact factor: 7,933 – Citations: 30**)
 116. Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA: Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. *Clin Exp Rheumatol* 30: 31-38, 2012 (**Impact factor: 2,724 – Citations: 25**)
 117. Katsanos KH, Voulgari PV, Tsianos EV: Inflammatory bowel disease and lupus: A systematic review of the literature. *J Crohns Colitis* 6: 735-742, 2012 (**Impact factor: 6,234 – Citations: 12**)
 118. Kotsis K, Voulgari PV, Tsifetaki N, Machado MO, Carvalho AF, Creed F, Drosos AA, Hyphantis T: Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. *Arthritis Care Res (Hoboken)* 64: 1593-1601, 2012 (**Impact factor: 4,713 – Citations: 27**)
 119. Kosta P, Voulgari P, Zikou A, Tsampoulas K, Drosos A, Argyropoulou M: Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. *Scand J Rheumatol* 41: 339-344, 2012 (**Impact factor: 2,527 – Citations: 2**)
 120. Voulgari PV, Kaltsonoudis E, Papagoras C, Drosos AA: Adalimumab in the treatment of rheumatoid arthritis. *Expert Opin Biol Ther* 12: 1679-1686, 2012 (**Impact factor: 3,743 – Citations: 8**)
 121. Katsanos KH, Voulgari PV, Goussia A, Oikonomou P, Christodoulou DK, Drosos AA, Tsianos EV: Coexistence of Crohn's disease in a patient with systemic lupus erythematosus. *Rheumatol Int* 33: 2145-2148, 2013 (**Impact factor: 1,516 – Citations: 2**)
 122. Saougou I, Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA: Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. *Joint Bone Spine* 80: 34-37, 2013 (**Impact factor: 2,901 – Citations: 19**)
 123. Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA: Adult-onset Still's disease: clinical, serological and therapeutic considerations. *Clin Exp Rheumatol* 31: 47-52, 2013 (**Impact factor: 2,724 – Citations: 9**)
 124. Chatzikiyriakidou A, Voulgari P, Georgiou I, Drosos A: Altered sequence of the ETS1 transcription factor may predispose to rheumatoid arthritis susceptibility. *Scand J Rheumatol* 42: 11-14, 2013 (**Impact factor: 2,527 – Citations: 8**)
 125. Filippatos T, Derdemezis C, Voulgari P, Tsimihodimos V, Elisaf M, Tselepis A, Drosos A: Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density

- lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. *Scand J Rheumatol* 42: 169-175, 2013 (**Impact factor: 2,527 – Citations: 9**)
126. Hyphantis T, Kotsis K, Tsifetaki N, Creed F, Drosos AA, Carvalho AF, Voulgari PV: The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis. *Clin Rheumatol* 32: 635-644, 2013 (**Impact factor: 1,696 – Citations: 23**)
127. Papagoras C, Voulgari PV, Drosos AA: Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. *Clin Exp Rheumatol* 31: 612-620, 2013 (**Impact factor: 2,724 – Citations: 37**)
128. Chatzikiyakidou A, Voulgari PV, Lambropoulos A, Georgiou I, Drosos AA: Validation of the TAGAP rs212389 polymorphism in rheumatoid arthritis susceptibility. *Joint Bone Spine* 80: 543-544, 2013 (**Impact factor: 2,901 – Citations: 0**)
129. Voulgari PV, Kosta P, Argyropoulou MI, Drosos AA: Avascular necrosis in a patient with systemic lupus erythematosus. *Joint Bone Spine* 80: 665, 2013 (**Impact factor: 2,901 – Citations: 0**)
130. Chatzikiyakidou A, Voulgari PV, Lambropoulos A, Drosos AA: Genetics in rheumatoid arthritis beyond HLA genes: What meta-analyses have shown? *Semin Arthritis Rheum* 43: 29-38, 2013 (**Impact Factor: 3,925 – Citations: 14**)
131. Markatseli TE, Voulgari PV: Subcutaneous calcifications in a patient with diffuse scleroderma. *Clin Exp Rheumatol* 31(2 Suppl 76): 180, 2013 (**Impact factor: 2,724 – Citations: 0**)
132. Gousias K, von Ruecker A, Voulgari P, Simon M: Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas. *J Neuroimmunol* 264: 84-90, 2013 (**Impact factor: 3,062 – Citations: 6**)
133. Chatzikiyakidou A, Voulgari PV, Drosos AA: Lack of association of the autophagy-related gene polymorphism ATG16L1 rs2241880 in RA predisposition. *Rheumatol Int* 34: 477-479, 2014 (**Impact factor: 1,516 – Citations: 1**)
134. Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, Kiortsis DN, Drosos AA: Cardiovascular risk profile in patients with spondyloarthritis. *Joint Bone Spine* 81: 57-63, 2014 (**Impact factor: 2,901 – Citations: 16**)
135. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P: Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. *Semin Arthritis Rheum* 43: 447-457, 2014 (**Impact factor: 3,925 – Citations: 17**)
136. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA: Demyelination and other neurological adverse events after anti-TNF therapy. *Autoimmun Rev* 13: 54-58, 2014 (**Impact factor: 7,933 – Citations: 34**)
137. Tzarouchi LC, Zikou AK, Tsifetaki N, Astrakas LG, Konitsiotis S, Voulgari P, Drosos A, Argyropoulou MI: White Matter Water Diffusion Changes in Primary Sjogren Syndrome. *AJNR Am J Neuroradiol* 35: 680-685, 2014 (**Impact factor: 3,589 – Citations: 1**)
138. Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA: Reply to the comment "Effect of Infliximab on Male Fertility" by Younis et al. *Joint Bone Spine* 81: 103, 2014 (**Impact factor: 2,901 – Citations: 0**)
139. Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA: Certolizumab for rheumatoid arthritis. *Clin Exp Rheumatol* 32: 415-423, 2014. (**Impact factor: 2,724 – Citations: 5**)
140. Tamas MM, Filippucci E, Becciolini A, Gutierrez M, Di Geso L, Bonfiglioli K, Voulgari PV, Salaffi F, Grassi W: Bone erosions in rheumatoid arthritis: ultrasound findings in the early stage of the disease. *Rheumatology (Oxford)* 53: 1100-1107, 2014 (**Impact factor: 4,475 – Citations: 7**)
141. Migkos MP, Markatseli TE, Iliou C, Voulgari PV, Drosos AA: Effect of hydroxychloroquine on the lipid profile of patients with Sjogren syndrome. *J Rheumatol* 41: 902-908, 2014 (**Impact factor: 3,187 – Citations: 7**)
142. Voulgari PV, Gaitanis G, Markatseli TE, Kempf W, Bassukas ID: In transit Recurrence of Merkel Cell Carcinoma Associated with Polyarthritis Effectively Treated with Immunocryosurgery. *Acta Derm Venereol* 94: 739-740, 2014 (**Impact factor: 3,720 – Citations: 1**)

143. Kotsis K, Voulgari PV, Tsifetaki N, Drosos AA, Carvalho AF, Hyphantis T: Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. *Rheumatol Int* 34: 1671-1681, 2014 (**Impact factor: 1,516 – Citations: 7**)
144. Chatzikyriakidou A, Voulgari PV, Drosos AA: Lack of association of the GSDMB gene at locus 17q12 with predisposition to rheumatoid arthritis. *Clin Exp Rheumatol* 32: 477, 2014 (**Impact factor: 2,724 – Citations: 1**)
145. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA: Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. *Arthritis Res Ther* 16: R125, 2014 (**Impact factor: 3,753 – Citations: 15**)
146. Gousias K, Voulgaris S, Vartholomatos G, Voulgari PV, Kyritsis AP, Markou M: Prognostic value of the preoperative immunological profile in patients with glioblastoma. *Surg Neurol Int* 5: 89, 2014 (**Impact factor: 0 – Citations: 1**)
147. Chatzikyriakidou A, Voulgari PV, Drosos AA: Non-HLA genes in ankylosing spondylitis: what meta-analyses have shown? Review. *Clin Exp Rheumatol* 32: 735-739, 2014 (**Impact factor: 2,724 – Citations: 1**)
148. Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T: Health-related quality of life in patients with ankylosing spondylitis: a comprehensive. Review. *Expert Rev Pharmacoecon Outcomes Res* 14: 857-872, 2014 (**Impact factor: 1,669 – Citations: 5**)
149. Voulgari PV, Drosos AA: Adalimumab in the treatment of rheumatoid arthritis. *Expert Opin Biol Ther* 14: 549-561, 2014 (**Impact factor: 3,743 – Citations: 5**)
150. Goulia P, Voulgari PV, Tsifetaki N, Andreoulakis E, Drosos AA, Carvalho AF, Hyphantis T: Sense of coherence and self-sacrificing defense style as predictors of psychological distress and quality of life in rheumatoid arthritis: a 5-year prospective study. *Rheumatol Int* 35: 691-700, 2015 (**Impact factor: 1,516 – Citations: 4**)
151. Papagoras C, Voulgari PV, Drosos AA: Golimumab, the newest TNF- α blocker, comes of age. *Clin Exp Rheumatol* 33: 570-577, 2015 (**Impact factor: 2,724 – Citations: 2**)
152. Tsifetaki N, Migkos MP, Papagoras C, Voulgari PV, Athanasakis K, Drosos AA: Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece. *J Rheumatol* 42: 963-967, 2015 (**Impact factor: 3,187 – Citations: 1**)
153. Gkolfinopoulou C, Stratikos E, Theofilatos D, Kardassis D, Voulgari PV, Drosos AA, Chroni A: Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. *J Rheumatol* 42; 1652-1660, 2015 (**Impact factor: 3,187 – Citations: 0**)
154. Migkos MP, Somarakis GA, Markatseli TE, Matthaïou M, Kosta P, Voulgari PV, Drosos AA: Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. *Clin Exp Rheumatol* 33; 734-736, 2015 (**Impact factor: 2,724 – Citations: 0**)
155. Petrikis P, Voulgari PV, Tzallas AT, Archimandriti DT, Skapinakis P, Mavreas V: Cytokine profile in drug-naïve, first episode patients with psychosis. *J Psychosom Res* 79; 324-327, 2015 (**Impact factor: 2,736 – Citations: 1**)
156. Chatzikyriakidou A, Voulgari PV, Drosos AA: Evidence of ERBB3 gene association with rheumatoid arthritis predisposition. *Int J Rheum Dis* 19: 146-149, 2016 (**Impact factor: 1,469 – Citations: 0**)
157. Voulgari PV, Gaitanis G, Fidhi L, Migkos MP, Bassukas ID. Joint complaints correlate with increased serum IgE levels in patients hospitalized for moderate-to-severe psoriasis: A single center retrospective study. *J Am Acad Dermatol*. 2016 May;74(5):1014-5.
158. Petrikis P, Boumba VA, Tzallas AT, Voulgari PV, Archimandriti DT, Skapinakis P, Mavreas V. Elevated levels of Insulin-like Growth Factor-1 (IGF-1) in drug-naïve patients with psychosis. *Psychiatry Res*. 2016 Dec 30;246:348-352. (**Impact factor: 2,837 – Citations: 0**)
159. Pelechas E, Gerolymatou N, Voulgari PV, Drosos AA. Transfusion-related acute lung injury in a patient with systemic lupus erythematosus. *Clin Exp Rheumatol*. 2017 Mar-Apr;35(2):353. (**Impact factor: 2,724 – Citations: 0**)
160. Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. *Expert Opin Biol Ther*. 2017 Jun;17(6):755-763

161. Voulgari PV, Apostolou F, Dounousi E, Liapis G, Elisaf M, Drosos AA. Uncommon presentation of granulomatosis with polyangiitis in association with subclinical coeliac disease. Clin Exp Rheumatol. 2017 Jun 9. [Epub ahead of print] (**Impact factor: 2,724 – Citations: 0**)
162. Petrikis P, Voulgari PV, Tzallas AT, Boumba VA, Archimandriti DT, Zambetas D, Papadopoulos I, Tsoulos I, Skapinakis P, Mavreas V. Changes in the cytokine profile in first-episode, drug-naïve patients with psychosis after short-term antipsychotic treatment. Psychiatry Res. 2017 Jul 3;256:378-383. doi: 10.1016/j.psychres.2017.07.002.
163. Pelechas E, Memi T, Voulgari PV, Drosos AA. A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor. Rheumatol Ther. 2017 Dec;4(2):509-513.
164. Thomas K, Flouri I, Repa A, Fragiadaki K, Sfrikakis PP, Koutsianas C, Kaltsonoudis E, Voulgari PV, Drosos AA, Petrikkou E, Sidiropoulos P, Vassilopoulos D. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clin Exp Rheumatol. 2017 Nov 9. [Epub ahead of print]
165. Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18:317–322.
166. Chatzikiyriakidou A, Voulgari PV, Drosos AA. An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility. Arch Rheumatol 2018;33:33-38.
167. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol. 2018;45:785-794.
- Your above referenced article has been selected by our Editor-in-Chief for inclusion in the next issue of CLINICAL HIGHLIGHTS for the Rheumatologist, with distribution in the USA. 11-5-2018 (email)*
168. Migkos PM, Sarmas I, Somarakis AG, Voulgari VP, Tsamis IK, Drosos AA. Sjögren Syndrome Associated with Inflammatory Muscle Diseases. Mediterr J Rheumatol 2018;29:92-6
169. Christina Tsalapaki Chr, Nikitopoulou E, Boki AK, Boumpas D, Sfrikakis PP, Vosvotekas G, Voulgari VP, Vassilopoulos D. Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. Mediterr J Rheumatol 2018;29:103-5.
170. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. 2018 Jun 22. pii: S0049-0172(18)30188-4.
171. Gaitanis G, Voulgari PV, Bassukas ID. Image Gallery: Capillaroscopy for noninvasive scabies diagnosis. Br J Dermatol. 2018 Sep;179(3):e133.
- Has been selected by the BJD for the open access digital forum Figure 1 (<https://figure1.com>).*
172. Migkos MP, Somarakis GP, Markatseli TE, Voulgari PV, Drosos AA. Epidemiological characteristics of psoriatic arthritis. Clin Exp Rheumatol. 2019;37(2):324-332.
173. Bogdos E, Markoula S, Zikou A, Voulgari P, Drosos A, Konitsiotis S. Demyelinating central nervous system lesions, following the use of tumor necrosis factor alpha antagonist. Neuroimmunol Neuroinflammation 2018;5:19.
174. Voulgari PV, Tatsi V, Millionis HJ, Goussia A, Xydis V, Glantzounis GK. Liver perivascular epithelioid cell tumor in a patient with systemic lupus erythematosus. Int J Surg Case Rep. 2018;53:193-195.
175. Panopoulos S, Tektonidou M, Drosos AA, Liossis SN, Dimitroulas T, Garyfallos A, Sakkas L, Boumpas D, Voulgari PV, Daoussis D, Thomas K, Georgiopoulos G, Vosvotekas G, Vassilopoulos D, Sfrikakis PP. Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Res Ther. 2018;20:267.

176. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. *Rheumatol Int.* 2019;39:353-357.
177. Touloumi, Giota; Karakatsani, Anna; Karakosta, Argiro; Sofianopoulou, Eleni; Koustenis, Panagiotis; Gavana, Magda; Alamanos, Yannis; Kantzanou, Maria; Konstantakopoulos, George; Chrysoschoou, Xenia; Benos, Alexis; Vantarakis, Apostolos; Hadjichristodoulou, Christos; Chlouverakis, Gregory; Trypsianis, Gregory; Voulgari, Paraskevi V; Makrilakis, Konstantinos; Liatis, Stavros; Stergiou, George. National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population. EMENO Study Group. *JMIR research protocols* 2019;8: e10997.
178. Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. *Rheumatol Int.* 2019;39:663-668.
179. Pelechas E, Voulgari PV, Drosos AA. Golimumab for Rheumatoid Arthritis. *J Clin Med.* 2019;8. pii: E387.
180. Kaltsonoudis E, Pelechas E, Papoudou-Bai A, Markatseli TE, Elisaf M, Voulgari PV, Drosos AA. The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. *PLoS One.* 2019;14:e0210845.
181. Drosos AA, Pelechas E, Voulgari PV. Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. *Rheumatol Int.* 2019 May 22.
182. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. *Rheumatology (Oxford).* 2019 Jun 6. pii: kez206.
183. Tsirves GK, Voulgari PV, Pelechas E, Asimakopoulos AD, Drosos AA. Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. *Eur Arch Otorhinolaryngol.* 2019 May 30.

E-PUBLICATION

1. Drosos AA, Tsifetaki N, Kitsos G, Alamanos Y, Voulgari PV: Reply to Dr Chan et al's comments on oral pilocarpine for ocular symptoms in Sjogren's syndrome (eLetter). <http://ard.bmjournals.com/cgi/eletters/62/12/1204#52>

H-INDEX

ISI Web of Science h-Index: 36

Scopus h-Index: 39

Google Scholar h-Index: 39